在没有吸烟者和轻度吸烟者中,IV期NSCLC的生存模式和突变概况
Kholoud Alqasem1, Sakhr Alshwayyat2,3,4, Salsabeel Aljawabrah5
1Department of Internal Medicine, King Hussein Cancer Center, Queen Rania Al Abdullah Street, P.O. Box: 1269, Amman, 11941, Jordan.
BMC cancer
|December 23, 2025
概括
这项研究将从未吸烟和轻度吸烟的人与约旦的第四阶段非小细胞肺癌 (NSCLC) 进行了比较. 从未吸烟者更常是女性,而轻度吸烟者是男性,观察到不同的EGFR突变配置文件.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 流行病学 流行病学
背景情况:
- 从未和轻度吸烟者非小细胞肺癌 (NSCLC) 占病例的很大一部分,但来自中东的数据很少.
- 了解这些患者群体的独特特征对于有针对性的治疗策略至关重要.
研究的目的:
- 为了比较临床病理特征,生存结果,以及从未和轻度吸烟者与IV期NSCLC的分子变化.
- 为约旦提供特定区域的数据,以告知精确瘤学.
主要方法:
- 从2015年1月到2023年12月的第四阶段NSCLC患者数据的回顾性审查.
- 从未吸烟者 (<100个终身香烟) 和轻度吸烟者 (<5个包年) 的定义.
- 卡普兰-梅尔分析和单变Cox模型用于生存和预后变量.
主要成果:
- 分析了190名患者 (159名从未吸烟者,31名轻度吸烟者);观察到明显的性别分布.
- 轻度吸烟者 (80.6%) 的EGFR突变比从未吸烟者 (58.5%) 更频繁.
- 从未吸烟者为61%,轻度吸烟者为54.8%;EGFR阴性瘤显示出更好的长期生存率.
结论:
- 患有IV期NSCLC的从未吸烟者和轻吸烟者表现出不同的临床和分子特征.
- 可操作的EGFR变化的高率强调了需要进行全面的分子测试.
- 特定区域的数据对于为非传统风险群体开发精确瘤学策略至关重要.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.9K
相关概念视频
01:21Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K